Cardinal Health to buy Solaris Health for $1.9 billion, posts weak results

Cardinal Health announced a $1.9 billion acquisition of Solaris Health to expand its high-margin specialty business into urology, a strategic move aligning with broader industry trends. Despite this and a raised 2026 profit forecast driven by strong specialty medicine demand, the company's shares fell nearly 6% due to flat fourth-quarter revenue missing estimates, primarily from OptumRx contract losses, underscoring investor focus on immediate operational challenges over long-term strategic growth.

Analysis

Cardinal Health (CAH) is executing a clear strategic pivot towards higher-margin specialty care, evidenced by its $1.9 billion acquisition of Solaris Health. This move, which follows last year's $1.12 billion purchase of an oncology network, aligns with a broader industry trend where distributors like rival McKesson are acquiring community care operators to diversify revenue streams. However, this long-term strategy is currently overshadowed by immediate operational challenges. The market's adverse reaction, sending shares down nearly 6%, was a direct response to the company's fourth-quarter results, where flat year-over-year revenue of $60.16 billion missed analyst estimates, explicitly due to the loss of contracts with a major customer, UnitedHealth's OptumRx. Despite the top-line weakness, Cardinal Health delivered a slight beat on adjusted EPS at $2.08 and raised its 2026 profit forecast, betting that the very specialty segment it is expanding will drive future growth. This creates a disconnect for investors, pitting the company's strategic, forward-looking initiatives against tangible, near-term revenue headwinds and increased leverage from the debt-financed acquisition.

Key Decisions for Investors

• Investors should weigh the long-term strategic merit of the Solaris acquisition against the immediate headwind of the OptumRx contract loss, which is currently pressuring the stock.
• Monitor the company's ability to successfully integrate Solaris Health and realize synergies, as the deal is being financed with a combination of cash and new debt, which increases balance sheet risk.
• Closely track future revenue performance to validate the company's raised 2026 profit guidance, ensuring that growth in the specialty segment can effectively offset current weakness in the core distribution business.